The advancement of genomic analysis technology revolutionizes breast cancer research, as it provides better breast tumor classifications, which then leads to enhanced clinical management or precision oncology.
With over 1.3 million women worldwide diagnosed with gynaecological cancers in 2020, it’s more important now than ever to equip them with tools and resources to promote prevention and early detection of potential cancers.
SOPHiA GENETICS is excited to announce the launch of SOPHiA DDM™ Dispatch, a new way for our SOPHiA GENETICS Integrated Access partner labs to work with their clients. SOPHiA DDM™ Dispatch make its it easier to work with clients directly and control logistics within your lab.
SOPHiA GENETICS is excited to celebrate Clinical Trials Day. This blog dives a little deeper into the history of clinical trials and how they continue to advance healthcare.
Every person is unique. We can clearly see this within the more than one million genomic profiles from 70 different countries analyzed by our technology.
Third party sequencing services can enable increased access to NGS testing, but if institutions do not receive access to the raw data it can limit the insights they can gain. Doing the data analysis in house can allow you to harness the power of genomic data to reveal relevant variants.
SOPHiA GENETICS has reached a major milestone on a global scale by analyzing one million genomic profiles.
The field of precision medicine continues to evolve but remains steadfast in its goal to provide the right treatment to the right patients at the right time. This blog examines the evolution of precision medicine and how we can achieve its promise.
Larger panels may cast wider nets, but optimization with patented algorithms through our universal platform gives more actionable insights without sacrificing data quality.
Increased access to genomic testing can help fulfill the promise of making precision medicine accessible to all, but the upfront investment required for institutions to start their own sequencing labs remains a barrier. This challenge can be overcome by using sequencing service.
By leveraging expertly curated evidence, powered by JAX-CKB, and SOPHiA GENETICS’ patented algorithms through the SOPHiA DDM platform, users can then use OncoPortal™ Plus to accurately identify clinical associations and actionable biomarker profiles.
The President acknowledged that the US still has much further to come in advancing data-driven initiatives and that many Americans sadly do not realize the struggle of seeking answers during the cancer diagnostic journey until it’s too late.
